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 disease is a lysosomal storage disorder caused by mutations in the gene encoding 
glucocerebrosidase (GCase). It is currently treated by enzyme replacement therapy (ERT) using recombinant 
GCase expressed in mammalian cells (Cerezyme ). Although Cerezyme  is highly effective, it is one of the most 
expensive drugs currently available. The demand of  therapeutic glycoproteins has dramatically increased over 
the past years. Most of the recombinant glycoproteins in the market today are produced using mammalian cell 
lines (Lepenies and Seeberger, 2014). The interest in plant-made pharmaceuticals (PMPs) is heightened due to 
the safety from contamination by animal viral pathogens. However, the low production yield and the present of 
plant specific -glycans differing from -glycan structures produced in humans, are the obstacles to practically 
use plants for pharmaceutical glycoprotein production (Strasser, 2014).This research aims to produce human 
GCase using  plants with high yield and suitable -glycan structure for human therapy. 
 The use of expression cassettes to express a foreign gene in plants had a major influence on the 
production of various proteins. In this study, a translational enhancer and suitable terminator were utilized to 
obtain a powerful expression system for GCase production in  plants. The highest activity was 
observed in transgenic plants transformed with pAt-GC- -UTR) of the 
Arabidopsis alcohol dehydrogenase gene (AtADH) with the Arabidopsis heat shock protein (HSP) terminator. 
The purified GCase obtained by using two types of chromatography, i.e., Concanavalin A and phenyl 650C 
chromatography. A 1 mg of purified GCase can be obtained from 130-140 g of leaf (about 10 mature plants). 
 Plant production systems are among the most attractive alternatives for pharmaceutical protein 
production due to such advantages as high-scalability, and safety from human pathogen contamination. 
-xylose and core 1,3-fucose on plant's -glycan structures has been debated for 
their antigenic activity. In this study, RNA interference (RNAi) technology was used for down-regulation of the 
endogenous -acetylglucosaminyl transferase I (GNTI) expression in One glyco-engineered 
line ( GNTI-RNAi) showed strong reduction of plant specific -glycans, with only 9.1% of the total -glycan 
structures contained plant-type -glycans.  
 The recombinant GCase for ERT in Gaucher's disease patients requires terminal mannose for its 
therapeutic efficacy. The GNTI-RNAi plant was cross-pollinated with transgenic expressing 
human GCase. The -glycan structures that were presented on all of the four occupied -glycosylation sites of 
recombinant GCase in GNTI-RNAi plants (GCase ) showed that the majority (ranging from 73.3% up to 
85.5%) of the -glycans had mannose- -xylose and 1,3-
fucose epitopes. Moreover, GCase could be taken up into the macrophage cells via mannose receptors, and 
distributed into the liver and spleen, the target organs in the treatment of Gaucher's disease. Notably, the 
GNTI-RNAi line, producing GCase, was stable and the GNTI-RNAi plants were viable and did not show 
any obvious phenotype. Therefore, it would provide a robust tool for the production of GCase with customized -
glycan structures. 
 In summary, we could express human GCase in  plants, as much as 1.45% of human 
GCase in TSP by using the combination of 5' UTR of Arabidopsis ADH with the Arabidopsis HSP terminator.  
Glyco-engineered plant was generated by down-regulation of the endogenous GNTI. This is the 
first successful report on the GNTI-down regulated  plants that could change the majority of 
total -glycans from plant-specific type to high mannose-type. The human GCase mostly contained high 
mannose-type - -xylose and 1,3-fucose epitopes was 
successfully produced by cross-pollination of glyco-engineered plant with transgenic expressing 
human GCase. Both GCase  and GCaseWT could be taken up into the macrophage cells via mannose receptors, 
and distributed into the liver and spleen. Therefore, it would provide a robust tool for the production of GCase 
with customized -glycan structures suitable for Gaucher's disease therapy.
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